These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22698479)

  • 1. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
    Fernandes AP; Coelho EA; Machado-Coelho GL; Grimaldi G; Gazzinelli RT
    Curr Opin Microbiol; 2012 Aug; 15(4):476-85. PubMed ID: 22698479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.
    Resende DM; Caetano BC; Dutra MS; Penido ML; Abrantes CF; Verly RM; Resende JM; Piló-Veloso D; Rezende SA; Bruna-Romero O; Fernandes AP; Gazzinelli RT
    Vaccine; 2008 Aug; 26(35):4585-93. PubMed ID: 18588933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
    Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
    Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
    Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
    Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
    Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.
    Arora SK; Pal NS; Mujtaba S
    Exp Parasitol; 2005 Mar; 109(3):163-70. PubMed ID: 15713447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
    Thakur A; Kaur H; Kaur S
    Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.
    Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK
    Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis.
    Anand S; Madhubala R
    Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
    Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
    Front Immunol; 2018; 9():465. PubMed ID: 29599776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.